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clinical trials. If significant local relapse is prevalent in the high dose 
region then dose escalation could be considered. Using this technique, 
PET-CT imaging during treatment may identify those patients more 
likely to relapse locally allowing earlier salvage therapy. 
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Purpose/Objective: We previously showed that a moderately 
hypofractionated RT with Tomotherapy (41.4 Gy in 18 fractions) 
concomitant to oxaliplatin and 5-FU is effective and well tolerated 
and that rectal volume variations, assessed by daily MVCT performed 
by tomotherapy, are smaller and more stable during the second half 
of the treatment so that a margin of 0.5 cm around the rectum is 
sufficient to include more than 90% of its volumetric variations. These 
data, and the hypothesis that the residual tumor still visible on 
CT/MRI after 10 radiotherapy fractions and two cycles of 
chemotherapy, could represent a more radio-chemo resistant 
component of disease, suggest the adoption of adaptive tomotherapy 
approach in rectal cancer. 
The aim of the study was to investigate the feasibility of preoperative 
adaptive radio-chemotherapy by delivering a concomitant boost to the 
residual tumour during the last 6 fractions of treatment. 
 Materials and Methods: Twenty-five patients with T3/T4N0 or N+ 
rectal cancer were enrolled. Concomitant chemotherapy consisted of 
Oxaliplatin 100mg/m2 on days -14, 0, +14, and 5-FU 200mg/m2/day 
from day -14 to the end of radiotherapy (day 0 is the start of 
Radiotherapy). Radiotherapy consisted in the delivery of 41.4 Gy in 18 
fractions (2.3 Gy/fraction) with Tomotherapy to the tumor and 
regional lymph-nodes (PTV) defined on CT/MRI imaging. After 9 
fractions CT and MR were repeated for the planning of the adaptive 
phase: PTVadapt was generated by adding a 5mm margin to the residual 
tumour. In the last 6 fractions, a boost of 3.0 Gy/fr (in total 45.6 Gy 
in 18 fractions) was delivered to PTVadapt while concomitantly 
delivering 2.3 Gy/fr to PTV outside PTVadapt. 
Results: Three patients experienced G3 gastrointestinal toxicity; 
toxicity occurred before the adaptive phase in 2/3 patients. A full 
dose of RT, Oxaliplatin, and 5-FU was delivered in 96%, 96%, and 88% 
of patients, respectively. Two patients with clinical complete 
response (cCR) refused surgery and were still cCR at 17 and 29 
months. For the remaining 23 resected patients, 15/23 (65%) showed 
TRG3 response and 7/23 had pathological complete response (pCR, 
30%); 8 (35%) and 12 (52%) TRG3 patients had ≤5% and 10% residual 
viable cells respectively. When considering cCR+pCR+TRG3 with viable 
cells<10%, the rate of major response was 84% (21/25). 
Conclusions: Adaptive boost strategy is feasible with an acceptable 
G3 GI toxicity rate and a very encouraging tumour response rate. The 
results suggest that there should still be room for further dose 
escalation with the aim of increasing pCR and/or cCR rates. 
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Purpose/Objective: To access the efficacy and safety of salvage 
oesophagectomy after failed definitive chemoradiotherapy for 
advanced esophageal cancer. 
Materials and Methods: A systematically literature searches of 
Medline, Embase, ISI Web of Knowledge, Cochrane Library and China 
Biological Medicine Database were undertaken in October 
2012.Clinical studies about salvage oesophagectomy were included 
without language or study design restriction. The studies of a sample 
less than 10 were excluded for inexperience of salvage 
oesophagectomy. The primary outcomes were survival and 
complication. The quality of including studies was accessed using the 
Oxford 2011 Levels of Evidence. Hazard ratios (HRs) for overall 
survival (OS) were combined with an inverse variance method based 
on logarithmic conversion. Odds ratios (ORs) and mean difference 
(MD) with 95% confidence intervals (CIs) were used to analyze 
dichotomous and continuous variables, respectively. All statistical 
analyses were undertaken in Review Manager 5.1 and random effect 
model was used. 
Results: Ten studies (8 cohort and 2 uncontrolled studies) were 
included, the quality of included studies was poor. Overall 307 
patients performed salvage oesophagectomy. The 1-, 3-and 5-years OS 
rates in salvage oesophagectomy group based on 265 patients were 
66%, 41%, and 32%, respectively. Pooled analyses based on 2 studies 
demonstrated that salvage oesophagectomy was associated with 
longer survival than non-surgery treatment after local failure of 
definitive chemoradiotherapy, the HR of OS was 0.39(95%CI:0.24-0.65; 
p=0.0003). but when compared with planned surgery, meta-analyses 
based on 6 studies suggested that salvage oesophagectomy was 
associated with worse survival (HR=1.66,95% CI:1.11-2.47; p=0.01), 
and higher in-hospital mortality (OR=2.99,95%CI:1.67-5.35;p=0.0002), 
longer hospital stay (MD=8.35,95%CI:1.86- 14.85; p=0.01),more 
anastomotic leak (OR=2.56,95%CI:1.38-4.74;p=0.003), more wound 
infection(OR=1.98,95%CI:1.10-3.59; p=0.02), more pulmonary event 
(OR=1.86,95%CI:1.32-2.63; p=0.004).The primary prognostic factors 
for favorable survival after salvage oesophagectomy were complete 
resection (HR=3.76; p<0.00001) based on 5 studies and early tumor 
stage (HR=7.5; p=0.08)based on 3 studies. One including study 
reported that the outcome in patients with remnant tumors was 
poorer than in those with recurrence (p<0.01). 
Conclusions: With the rare clinical evidence, salvage oesophagectomy 
was considered as a hopeful treatment after local failure of definitive 
CRT. But with more complication and higher surgical difficulties than 
planned surgery, patients should be chosen more carefully. 
Meanwhile, higher surgical technique was required on surgeon. 
Because of the small sample and the low quality of current studies, 
more clinical studies are still needed. 
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Purpose/Objective: To retrospectively evaluate efficacy and toxicity 
of radio- ± chemotherapy (RT ± CT) in the management of anal canal 
carcinoma. 
Materials and Methods: Data of patients (pts) with an histological 
diagnosis of anal canal carcinoma were reviewed. Local Control (LC) 
and the acute and late toxicity rates were the primary endpoints of 
the analysis.Secondary endpoints are listed in Table 1. 
Results: From 02/1992 to 10/2010, 100 pts (M/F ratio: 17/83)were 
treated with curative RT with (58 pts) or without (42 pts) 
chemotherapy. Median age was 70 years (range: 33-91). According to 
the 2002 UICC TMN classification,13, 51, 14 and 22 tumors were 
staged as Stage I, II, IIIa and IIIb,respectively. 29% of the pts were N1-
3 and 14 pts presented positive inguinal nodes. Following the clinical 
conditions, RT was delivered on the initial tumor site with (68%) or 
without (32%) pelvic irradiation (upper field border: L5-S1) with a 
standard fractionation (1.8/2Gy). Median dose on the pelvis was 45Gy 
(range: 36-54), while a median total dose of 60Gy (range: 38-70)was 
delivered on the anal canal. Bilateral inguinal irradiation was 
delivered in 70 pts,with a curative (13%, one groin N+ patient having 
received lymphadenectomy before RT) or a prophylactic (57%) goal, at 
a median dose of 36Gy (range:36-66.6Gy). Median LC time was not 
reached, while 5- and10-years LC rates were 73% and 67%, 
respectively. Overall acute and late G3-4 toxicity rates were 32% 
(particularly skin G3 toxicity, 30/32 pts) and 18% (particularly rectal 
G3 toxicity, 7/18 pts), respectively, with 22 pts having undergo a 
colostomy, but with only 2 pts having received it to treat a G4 anal 
toxicity. All these pts received colostomy in the first 3 years after the 
end of the RT±CT. Sphincter function was evaluated in the remaining 
78 pts (with the Womack scale) and classified as a total continence or 
incontinence to gazes (score A-B) in 73 pts and a sincontinence to 
liquid stools (score C) in 5 pts or total incontinence (score D) in 2 pts. 
Table 1 shows results of the univariate and multivariate analysis on 
the primary and secondary endpoints. 
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Conclusions: RT±CT achieve good LC rates in anal canal cancer 
patients. In our experience, local response and LC statistically 
influenced the Cancer Specific Survival and the risk of systemic 
relapse. High acute skin toxicity rates probably impose to tailor 
volumes and techniques of irradiation following the patient and tumor 
characteristics (more tailored indications for inguinal RT?). 
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Purpose/Objective: Chemoradiation is worldwide considered the 
standard treatment of anal cancer, with a high rate of sphincter 
preservation, local control and survival. However, this strategy often 
leads to significant acute morbidity, playing a negative impact on 
clinical outcome. New technological advances could improve dose 
delivery and therapeutic index ratio. As IMRT allows simultaneous 
integrated boost (SIB) of higher RT doses to the gross tumor volume 
and lower doses to normal tissue, our purpose is to evaluate if this 
recently introduced technique can result in a better outcome in terms 
of tolerance and clinical results for patients affected by anal 
carcinoma. 
Materials and Methods: Between February 2009 and October 2012, 31 
patients, median age 62 years, with stage I (6 pts), II (6 pts), IIIA (8 
pts), IIIB (11 pts) were treated with RT±CT. 19 patients underwent 2 
courses of MMC and 5 FU (during the first and last week of RT); 3 pts 
received Capecitabine concurrent with RT; 3 pts received 
Capecitabine and MMC. IMRT with SIB was delivered by Helical 
Tomotherapy (HT) in 24 patients and by a Linac-based step & shoot 
technique in 7. The prescribed doses were 50.6-55 Gy to CTV1 
(primary tumor, involved nodes and high risk area) and 41.4-45 Gy to 
CTV2 (low risk subclinical disease), in 23-25 daily fractions. 
Megavoltage CT scans were obtained for patient alignment before 
each treatment in the group treated with HT while weekly portal 
images were performed in the other group. The clinical status during 
RT was analyzed through the evaluation of supportive care type 
defined by analgesic need. 
Results: All patients received the prescribed dose and none had 
treatment breaks due to acute toxicity, except for one, who refused 
to conclude treatment, receiving 50.6 Gy on CTV1 in 23 fractions. For 
all patients, dose volumes results for CTVs are reported in the table. 
Mean doses to bladder and bowel were respectively 28.5 and 16.4 Gy. 
The median follow-up is 12 months (range 1-36). The most significant 
severe genitourinary acute toxicities reported at treatment end were 
grade 3 vaginal bleeding (3%) and grade 2 vaginal burn (6%). 
Cutaneous grade 3 erythema was recorded in 20% of patients and 
grade 2 gastrointestinal toxicities in 16%. Generally, skin toxicity 
appeared in the last week of RT and recovered in 2 weeks. 16 (53%) 
patients needed analgesic support (tramadol, codeine or major 
opioids). At a minimum FU of 4 months, 22 patients are evaluable for 
clinical response: 19 (86%) patients achieved complete response (CR), 
2 patients underwent local progression after initial partial response 
(PR) and one patient had progressive disease (PD). One patient died 
for PD. 
 
 
 
 
 
 
 
 
 
 
Conclusions: IMRT with SIB achieves great homogeneity in the dose 
distribution and a significantly good sparing of the organs at risk, also 
shortening total treatment time. The combined chemo-radiotherapy 
also shows excellent results in terms of toxicity and local control.  
 
 POSTER: CLINICAL TRACK: GENITOURINARY 
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Purpose/Objective: Stereotactic Body Radiation Therapy (SBRT) take 
advantage of the prostate low a/b ratio to deliver a large radiation 
dose in few fractions. Recent technological developments, combined 
with modern understanding on prostate radiobiology have generated 
enthusiasm for hypofractionated regimens. We report our preliminary 
results with Cyberknife stereotactic radiosurgery in patients with 
clinically localized prostate cancer. 
 Materials and Methods: From July 2007 to October 2011, 107 
patients with a median age of 75 (range 60– 86) years, a T1c –T2 b 
prostate cancer were treated with Cyberknife stereotactic 
radiosurgery at our institution. The majority of patients 59 (55%) were 
low risk , 28 pts (26%) were intermediate risk and 19 pts (19%) were 
high risk patients using the NCCN criteria . Pre-treatment PSAs ranged 
from 1.75 to 23.88 ng.ml (median 7.4 ng.ml). Among the entire study 
cohort 7 of 19 high risks patients received androgen deprivation 
therapy (ADT), ADT was not administered to any low – intermediate 
risk patients A prescribed dose of 38 Gy in four fractions was delivered 
to the PTV, which was defined as the prostate (plus seminal vesicles 
in High risk patients) expanded 3 mm posteriorly and 5 mm elsewhere. 
Real-time intrafractional motion tracking was used. Biochemical 
control was assessed using the nadir+2 (Phoenix) definition.  
Results: All patients were placed on A-blockade medication at the 
beginning of Cyberknife radiosurgery treatment. Acute side effects 
were generally mild and resolved shortly after treatment. No rtog 
grade 4 acute or late ractal/urinary complications was observed. 3 
patients developed Grade 3 late urinary toxicity following repeated 
urological instrumentation, including cistoscopy and urethral 
dilatation. Four patients, one with prior Turp, experienced 
incontinence, one 9 months after treatment, two 12 months after 
treatment, one 27 months later. One patient experienced rectal 
incontinence 12 months after treatment. The actuarial median follow 
up is 30 months (range 12 – 60 months). The four years actuarial psa 
relapse free survival rate is 93.9% (CI: 88.0%-99..8%). To date 5 
patients failed biochemically. One low risk patient revealed local 
relapse 30 months after Cyberknife treatment. One high risk patient 
developed bone metastases, in 2 intermediate and in 1 high risk 
patient we observed nodal metastases. All patients are alive except 
four died of unrelated causes. 
Conclusions: Cyberknife SBRT produces excellent biochemical control 
rates at up to 4 years with mild toxicity and minimal impact on quality 
of life. Median PSA levels compare favourably with other radiation 
Volume/Gy Prescription 
Dose (Gy) 
Mean 
Dose 
Max 
Dose 
Min 
Dose 
CTV55 55 54.9 56.8 51.4 
CTV50.6 50.6 51 52.9 47.7 
CTV45 45 47 55.9 38.4 
CTV41.4 41.4 42.5 52 39.3 
